Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported that it has repurchased an additional 250,000 shares of common stock in the open market at an average price of about $0.2782 per share. This brings total buybacks under its existing repurchase program to 4,838,000 shares for approximately $1.04 million.
The authorized program allows for share repurchases of up to $5 million and is set to run through December 31, 2026, with the option for renewal at the company’s discretion. Cosmos Health plans to continue open market repurchases, subject to market conditions, in accordance with SEC Rules 10b5-1 and 10b-18.
Positive
- 4,838,000 shares repurchased to date for approximately $1.04 million
- Active buyback program authorized up to $5 million through December 31, 2026
- Recent additional repurchase of 250,000 shares at about $0.2782 per share
Negative
- Share repurchases represent a cash outlay of approximately $1.04 million to date
News Explained
The
Sources and calculations
- Cosmos Health share buyback update (2026-07-16)
- Cosmos Health first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $5,000,000 / ($1,067,066 / 90) = [object Object]
News Market Reaction – COSM
In the Jul 16 session, COSM gained 0.79%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.4% during that session. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 15 | Share buyback update | Positive | -9.3% | Announced total 4,588,000 shares repurchased under up to $5 million program. |
| Jul 14 | Share buyback update | Positive | -4.3% | Reported total repurchases reaching about 4,488,000 shares for roughly $941,000. |
| Jul 13 | Share buyback update | Positive | +5.4% | Disclosed total 4,355,000 shares bought back for approximately $901,000. |
| Jul 09 | Share buyback update | Positive | -1.0% | Expanded total buybacks to 4,140,000 shares for about $831,000. |
| Jul 08 | Share buyback update | Positive | +2.8% | Reported surpassing 4,060,000 shares repurchased under the up to $5 million plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent buyback updates have produced mixed reactions, with slightly more negative than positive 1-day moves around these announcements.
Key Terms
sec rules 10b5-1 regulatory
sec rules 10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately
The Company has now repurchased a total of 4,838,000 shares for approximately
The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company's sole discretion.
Greg Siokas, CEO of Cosmos Health, stated: "Crossing
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
